Margriet Kwint

Chapter 3 64 Although all of our patients had synchronous oligometastatic NSCLC at diagnosis, our study population remains heterogeneous since we included patients with different types of NSCLC histology, metastases in different organs and allowed different treatment regimens. Therefore, the statistical power of this analysis is too low to identify subgroups of patients who will benefit from a radical treatment. In conclusion, radical local treatment of a selected group of NSCLC patients with good performance presenting with synchronous oligometastatic stage IV disease resulted in favorable long-term PFS and OS. Radical local treatment strategies should be part of future prospective studies and compared with standard therapy.